background: Adipose tissue contains an abundant population of multipotent adipose-derived stem cells (ASCs) and has been an excellent source of mesenchymal stem cells for cell therapy and tissue engineering. To ensure successful cell therapies, consistency of stem cell performance across donors is critical. However, the effect of the donor's reproductive status on ASC proliferation rate and differentiation capacity is undefined.
Introduction
Adipose tissue has recently been shown to be an excellent source of mesenchymal stem cells (MSCs), giving multipotent cells called adipose-derived stem cells (ASCs). Unlike bone marrow, adipose tissue is readily accessible and can be extracted in a large volume with limited morbidity, which therefore minimizes the time in culture required to generate a therapeutic cell dose (Strem et al., 2005) . These properties make ASCs a particularly attractive reservoir of progenitor cells suitable for therapeutic use. However, to successfully apply ASCs in clinical therapies, the consistency of their performance across different donors must be ensured. Many factors might influence both the proliferation rate and differentiation capacity of ASCs, such as donor age, type of adipose tissue used (white or brown adipose tissue), localization of the adipose tissue (subcutaneous or visceral adipose tissue), tissue-harvesting procedures, isolation methods, culturing conditions, media formulations and plating density (Lee et al., 2004; Van Harmelen et al., 2004; Oedayrajsingh-Varma et al., 2006; Peptan et al., 2006; PrunetMarcassus et al., 2006; Smith et al., 2006; Lei et al., 2007) . In addition to these factors, reports have also shown that hormones including estrogen can stimulate proliferation in mouse ESCs and affect the differentiation capacities of human MSCs (Han et al., 2006; Hong et al., 2006) . The level of sex hormones, including estrogen, changes dramatically at different times in a woman's life, so that stem cells isolated from women at different stages of the reproductive cycle may be influenced by these hormonal changes. However, this has not been studied.
Therefore, in this study, we investigated the effect of reproductive status and the level of the reproductive hormone estrogen on the proliferation and differentiation capacities of ASCs. We collected ASCs from 15 donors and divided them into three groups according to reproductive status: pregnancy, premenopause or menopause. The growth characteristics and differentiation potentials of the ASCs were compared with determine whether there were any differences between the three groups.
Materials and Methods

Acquisition of human tissues
The authors' institutional review board approved the study. Informed consent was obtained prior to tissue collection. Fifteen female subjects who were undergoing Caesarean section or total abdominal hysterectomy (TAH) were recruited at the authors' hospital. Subjects who had concomitant malignant pelvic diseases or who were receiving estrogen replacement therapy were excluded. The 15 donors were neither obese or underweight. They were divided into three groups according to their reproductive status: pregnancy, premenopause or menopause. A standardized biopsy site on the abdomen was selected and a subcutaneous adipose tissue sample was obtained. The samples were freed from surrounding muscular tissues and blood vessels.
Culture of ASCs
To isolate human ASCs, each sample of adipose tissue was washed extensively with sterile phosphate-buffered saline (PBS) to remove contaminants. Then the tissues were digested at 378C for 1 h with 0.075% type IV collagenase in plain Dulbecco's Modified Eagle Medium:nutrient Mix F-12 (DMEM/F12). After digestion, released cells were collected by centrifugation at 1200g for 10 min. Then the pellet was re-suspended with plain DMEM/F12 and centrifuged for another 10 min. Finally, the cells in the pellet were seeded on to 100 mm plastic tissue culture dishes in control medium containing DMEM/F12, 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 mg/ml streptomycin. The cells were incubated in a humidified atmosphere of 5% CO 2 at 378C. Culture medium was replaced after 24 h to remove residual non-adherent red blood cells. All culture media and reagents were purchased from Gibco BRL Life Technologies, Inc. (Carlsbad, CA, USA).
Flow cytometric analysis
ASCs at the fifth passage were harvested in 0.25% trypsin/EDTA (Gibco) and washed with PBS. Cells were aliquoted into 3 Â 10 5 cells per tube and were blocked with human serum for 15 min. Then they were incubated in PBS containing 1 ml monoclonal antibodies to CD44 and CD90 at 48C for 1 h. After washing with PBS, the cells were incubated with Alexa Fluor 488 secondary antibodies (Invitrogen, Carlsbad, CA, USA) at room temperature for 15 min. As control, cells were stained with isotypic control IgG1, l (Abcam Ltd, Cambridge, MA, USA). All antibodies were purchased from BD Biosciences (Palo Alto, CA, USA). Flow cytometry was performed on a Beckman Coulter Altra flow cytometer (Beckman Coulter, Miami, FL, USA). In all cases, at least 20 000 cells were collected and the data was analysed using Expo32 MultiComp software (Beckman Coulter).
Measurement of cell growth
ASCs were seeded into 6-well plates at cell density of 2.5 Â 10 4 cells/well in duplicate, and the cell number was determined with trypan blue (Sigma, St Louis, MO, USA) exclusion assay at 3 day intervals until Day 14. A growth curve was plotted for each sample as log cell number versus time. The growth rates were derived from the slope of each growth curve.
Effect of E 2 treatment on ASC proliferation
ASCs at fifth passage were seeded on to a 24-well plate at a density of 1 Â 10 4 cells/well in culture medium (DMEM/F12þ10% charcoal-treated FBS) (Gibco). All cells were starved for 24 h before the experiment. On Day 0, the culture medium was replaced by medium containing DMEM/F12 supplemented with 2% charcoal-treated FBS with or without addition of 17b-estradiol (Sigma) at a concentration of 10 28 mol/l. The proliferation rates were determined by 3-(4,5,-dimethyl thiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) cell proliferation assay. ASCs were harvested on Day 1, Day 3, Day 6 and Day 9. In brief, 300 ml MTT reagent (Sigma) was added to each well 2 h prior to harvest. The supernatant was then removed and incubated with 400 ml dimethylsulphoxide for 10 min. Absorbance at 570 nm was recorded using an enzyme-linked immunosorbent assay plate reader.
Chondrogenic differentiation of ASCs
ASCs at the fifth passage were pretreated with 5 ng/ml fibroblast growth factor-basic (bFGF) (Invitrogen), one passage before induction. Chondrogenic differentiation was induced using the micromass culture technique (Ahrens et al., 1977) . Ten microlitres of ASC suspension at a concentration of 1 Â 10 7 cells/ml was plated into the center of each well and allowed to attach at 378C for 3 h. Chondrogenic medium containing DMEM/F12, 10% FBS, 10 ng/ml transforming growth factor-b1 (TGF-b1) (Sigma), 100 nM dexamethasone (Sigma), 6.25 mg/ml insulin (Sigma), 50 nM ascorbate-2-phosphate (Sigma), 110 mg/l sodium pyruvate (Gibco) and 1% P/S (protocol modified from Lee et al., 2004) was added gently to the cell nodules and the cells were collected after 3, 7, 14, 21 and 28 days of culture.
Immunohistochemical analysis of stem cell markers and chondrogenic markers
After chondrogenic induction, spheroids formed during the micromass culture were fixed in 4% buffered paraformaldehyde overnight. Then the spheroids were dehydrated, embedded in paraffin blocks and cut into sections of 5 mm for immunostaining studies. The sections were microwaved at high power for 4 min in citrate buffer (pH 6.0) to release antigens and then blocked in 3% bovine serum albumin at room temperature for 30 min. Then they were incubated at room temperature for 2 h with the antibodies against two MSC markers CD44 and CD90 (BD Biosciences), as well as three chondrogenic markers SOX9 (Chemicon International, Inc., Temecula, CA, USA), Aggrecan (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and Collagen Type II (MP Biomedicals, Irvine, CA, USA). The cells were then immunofluorescently labelled by incubation for 1 h with Alexa secondary antibodies (Invitrogen). Sections were mounted with ProLong Gold antifade mount with DAPI for microscopy. Negative controls using secondary antibodies alone were also prepared to rule out non-specific labelling.
Alcian Blue staining
Sections of chondrogenic-induced spheroids were stained in 1% aqueous Alcian Blue solution (Sigma) for 30 min and washed in distilled water. Then the cells were dehydrated, cleared and mounted for microscopy.
RNA extraction and RT-PCR analysis
Total RNA was extracted from differentiated ASCs by Trizol reagent (Molecular Research Center Inc, Cincinnati, OH, USA) according to the manufacturer's instructions. Extracted RNA was then reverse-transcribed to cDNA using SuperScript TM First-Strand Synthesis Kit (Invitrogen) and quantified as previously described (Liu et al., 2006) . In brief, amplifications Pregnant women show higher proliferation rate for ASCs of chondrogenic markers SRY (sex determining region Y)-box 9 (SOX9), collagen type II, alpha 1 (COL2A1) and collagen type X, alpha 1 (COL10A1) were performed in a final reaction volume of 5 ml in 384-well plate format using ABI PRISM 7900HT Sequence Detection System. Fluorescence signals collected were analysed by SDS 2.1 software (Applied System) and relative expression levels were determined by normalization with endogenous GAPDH mRNA levels. The primer sequences used are summarized in Table I .
Western blot analysis
Total protein was extracted from samples after micromass culture as previously described (Lemons et al., 2001) . In brief, cell pellet was lysed with 4 M guanidine hydrochloride containing proteinase inhibitor. Lysates were centrifuged at 14 000g for 15 min at 48C. The supernatants were precipitated overnight with 3 volumes of cold ethanol and 5 mM sodium acetate at 48C. Precipitated proteins were collected by centrifugation at 14 000g for 60 min at 48C. After removal of ethanol, each pellet was re-suspended in 50 ml digestion buffer (50 acetate and 10 mM EDTA, pH 8.0, 0.9 U chondroitinase ABC) for 3 h at 378C. Protein concentration was determined using the Bradford method (Bio-rad, Hercules, CA, USA). Thirty micrograms of cell extracts were separated on 10% sodium dodecyl sulphate-polyacrylamide gels and transferred onto nitrocellulose membrane (Amersham, Buckinghamshire, UK). After blocking with 5% non-fat milk, the membrane was probed with goat anti-aggrecan (1:200) (Santa Cruz Biotechnology, Inc.) or mouse anti-actin (1:1000) (Cell Signaling) antibodies at 48C overnight. After three washes with 20 mM Tris-buffered saline containing 0.1% Tween-20 and 137 mM sodium chloride (TBS-T) for 10 min each, the membrane was incubated for 1 h in horse-radish peroxidase conjugated donkey anti-goat IgG antibodies (1:5000) (Santa Cruz Biotechnology, Inc.) or rabbit anti-mouse IgG antibodies (1:5000) (Cell Signaling) depending on the species of primary antibodies used. Following three washes of membrane in TBS-T for 10 min each, signal was developed using the Western Lightning Reagent Plus (Perkin-Elmer, Boston, MA, USA) and detected using X-OMAT Blue film (KODAK).
Results
Isolation and characterization of ASCs
A total of 15 adipose samples were collected from 15 un-related women with different reproductive statuses, after Caesarean section or TAH. Among the donors, four were menopausal, five were pregnant and six were premenopausal (Table II) . Their age ranged from 16 to 72 years old. ASCs were successfully isolated and cultured from all subjects. Isolated ASCs exhibited a fibroblast-like morphology (Fig. 1A) , and appeared similar to MSCs obtained from other tissues by other groups. The morphology as seen under the light microscope was similar among the three groups. Immunofluorescent staining consistently showed that both CD44 and CD90 were expressed in undifferentiated ASCs (Fig. 1B-C) . Further quantitative analysis by flow cytometry revealed that the majority of the isolated ASCs expressed CD44 (91 + 10%) and CD90 (79 + 8%), confirming their MSC characteristics (Fig. 1D ). There was no significant variation in CD44 and CD90 expression from ASCs derived from different individual samples.
Chondrogenic differentiation of ASCs
ASCs were chondrogenic-induced in micromass culture with chondrogenic medium containing TGF-b and dexamethasone for 28 days. On the day after cell seeding, the cells started to aggregate into a threedimensional spherical structure (Fig. 2B) . Each sample was analysed in duplicate and duplicates of the same sample showed similar shape and size. Control cells were also seeded in micromass culture, but were grown in ASC growth medium instead of chondrogenic medium. Control cells grew only in multilayer with no spherical structure ( Fig. 2A) . Immunofluorescent staining revealed the nuclear localization of SOX9 protein as well as the superficial deposition of collagen type II and aggrecan in spheroids (Fig. 3) after addition of chondrogenic medium. The chondrogenic differentiated ASCs had a significantly Pregnant women show higher proliferation rate for ASCs higher expression (7-15-folds increase) of mRNA of chondrogenic markers SOX9, COL2A1 and COL10A1 compared with control (Fig. 4) . The results of real-time PCR also showed the expression profile of these markers to be time-dependent. The SOX9 and COL2A1 transcripts were expressed in the early stage and peaked at Day 14 of differentiation while COL10A1 was expressed highly in the later stage (Day 28). ASCs that had differentiated into chondrocytes were stained positive with Alcian Blue (Fig. 2D) to a higher intensity than controls. This indicated the presence of proteoglycans, which are normally secreted into the extracellular matrix of the cartilage.
Effect of donor reproductive statuson the differentiation capacity of ASCs
To study the effect of donor reproductive status on the differentiation potential of ASCs, their differentiation potentials towards the chondrogenic lineage were compared. Expression levels of three chondrogenic markers SOX9, Aggrecan and Collagen Type II were studied by real-time PCR and immunostaining. The expression levels of the three markers and their staining intensity were scored, but no obvious differences were seen in differentiation potential between the three groups. This was further confirmed by aggrecan protein levels detected by western blot analysis (Fig. 5) . Our results demonstrated that ASCs derived from all donors, whether pregnant, premenopausal or menopausal, were able to produce aggrecan after chondrogenic differentiation and there were no significant differences between them (Fig. 5) .
Effect of donor reproductive status on cell proliferation capacity
The proliferation rates of the three groups were also compared with investigate the effect of reproductive status on the total number of surviving ASCs. Cell proliferation was monitored between Day 1 (one day after plating) and Day 10. Using the non-parametric Kruskal -Wallis test, we found that the pregnancy group showed a significantly higher proliferation rate than the other two groups (P , 0.05) (Fig. 6A) .
Effect of estrogen treatment on the proliferation rate of ASCs
To determine whether the higher proliferation rate in the pregnancy group was due to the higher level of estrogen present in pregnant women, the effect of E 2 on ASC was studied by MTT assay for cell proliferation. The growth rates of ASCs with and without estrogen were compared. By analysing the slope of the growth curve, our result showed that there was no significant difference between the two groups of samples (Fig. 6B ). In addition, no significant The expressions were time-dependent. SOX9 and COL2A1, which are early chondrogenic markers, were expressed in the middle of the differentiation period. COL10A1, which is a late marker, was expressed at a late stage of the differentiation period.
up-regulations of ER-alpha and ER-beta transcripts (data not shown) were found in either E 2 -treated or control ASCs.
Discussion
This is the first study examining the effect of donor reproductive status on the biological significance of ASCs. When we classified the samples into three groups according to their reproductive status (pregnancy, premenopause or menopause), we observed no significant difference in term of stem cell marker expression between the three sample groups. We also compared their differentiation potential towards the chondrogenic lineage in terms of their abilities to form spheroids as well as the expression level of chondrogenic markers after induction. Again, no obvious difference was found between the three groups. Our results provide important information for future therapeutic use, as the data suggests that ASCs can be isolated from different individuals of different age groups and reproductive statuses with no detrimental effect upon the nature of their stem cells. In addition, our data suggested that ASCs possess similar powers for differentiation regardless of the donor's reproductive status and age. Thus, cell therapies or transplantations involving the use of ASCs can be applied to any individual without regard to individual age or reproductive status. However, we have not examined differences between male and female. Interestingly, we found that the proliferation rate of ASCs in the pregnancy group was significantly higher than in the other two groups. In women, estrogen levels increase greatly during pregnancy. There have also been reports of the stimulation of stem cell proliferation by estrogen (Han et al., 2006; Hong et al., 2006) . Therefore, we hypothesize that the different estrogen levels in the pregnancy group may account for the variation. However, we cannot find any relationship between estrogen level and capacity for stem cell proliferation, as no significant difference was found between the groups. This suggests that the variation in estrogen levels among the three sample groups may not be the cause of their different proliferation rates, even though E 2 was shown to induce human neural progenitor cell proliferation in vitro (Wang et al., 2008) . Other possibilities may include the involvement of hormones other than estrogen, or other unknown factors which require further investigation.
In summary, ASCs are readily abundant and easily procured for cell therapy and tissue engineering. To successfully use ASCs for clinical therapies, the consistency of their performance across different donors must be ensured. By investigating the mRNA and protein expressions of a number of lineage markers, the differentiation capacity towards chondrogenic lineage was found to be totally unaffected by the donor's reproductive status. However, the proliferation rate of ASCs from pregnant women was significantly higher than from the other two groups. In vitro estrogen treatment of ASCs showed no significant effect on their proliferation rate, suggesting that the difference in proliferation between different reproductive statuses may be due to factors other than a difference in estrogen levels. Figure 6 (A) Boxplot comparing the growth rates of ASCs derived from the three reproductive groups. The growth rate was calculated from the slope of the growth curve, i.e. the cell numbers versus time (between Day 1 and Day 10). The growth rate of the pregnancy group is significantly higher than the other two groups (KruskalWallis Test, P , 0.05). (B) Graph comparing the relative proliferation rates of ASCs with and without E 2 treatment. No significant difference in the proliferation rate is found between the two groups.
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